API
< Back to all clusters
[BUSINESS] · France, United States · 3 sources

started · updated

BioMérieux confirms 2026 financial targets after strong Q3 results

BioMérieux, a specialist in in vitro diagnostics, has confirmed its 2026 financial objectives following third-quarter revenue that exceeded analyst expectations. For the period of July to September 2026, the company reported revenue of 1.04 billion euros, representing a 9.9% increase year-on-year and an 8.1% increase on an organic basis.

This performance was driven significantly by the Biofire non-respiratory panels, which saw sales growth of 25%. The company noted that a cyclosporinosis epidemic in the United States stimulated demand for the Biofire gastrointestinal panel. Excluding this specific epidemic effect, non-respiratory panel sales grew by approximately 15%.

Regarding its full-year outlook, BioMérieux expects organic revenue growth between 3% and 5%. The company also anticipates its contributory current operating result (ROCC) to remain stable or increase by a maximum of 10% on an organic basis. Following the announcement, the company's stock price saw a notable increase.

Entities

Biofire · ODDO BHF · TP ICAP Midcap · bioMérieux